Insight on Therapy Area in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Women's Health Market Strategies - Opportunities remain in this overlooked therapy area

This report aims to explore the opportunities and challenges in the women’s health sector. Market access is evaluated and includes analysis of drug sales, key players, regulatory trends, licensing deals, unmet needs, and marketing strategies.

Published By Datamonitor
12 Oct 2011 $2800
Buy
Report
Report

Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

This module discusses differential pricing for antiretrovirals as a strategy that enhances access to drugs while preserving incentives for pharmaceutical companies.

Published By Datamonitor
18 May 2011 $1520
Buy
Report
Report

Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success

Full analysis of the future urinary incontinence market. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) for key marketed brands, generics, and pipeline products.

Published By Datamonitor
15 Dec 2010 $6400
Buy
Report
Report

Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics.

Published By Datamonitor
22 Dec 2010 $15200
Buy
Report
Report

Forecast Insight: Antidiabetics - UPDATE 2: Bydureon delay boosts Victoza sales, but the status quo remains largely unchanged. Avandia sales restrictions lead to patient switching, opportunities for multiple drug classes.

Analysis of the competitive landscape and the recent changes in antidiabetics across seven major markets. Analysis of the threats to currently marketed drugs. Assessment of the opportunities available to novel agent classes.

Published By Datamonitor
22 Oct 2010 $15200
Buy
Report
Report

Forecast Insight: Asthma/COPD - Pipeline potential outweighs downward pressure from generics

Asthma and COPD market forecast for the seven major markets, incorporating the latest data from the European Respiratory Society 2010 Congress. Recent advances and setbacks of marketed/pipeline products and generics companies' actions are covered.

Published By Datamonitor
29 Sep 2010 $15200
Buy
Report
Report

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Datamonitor surveyed 183 rheumatologists in the seven major markets to gain insight into rheumatoid arthritis diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision making and key treatment challenges.

Published By Datamonitor
17 Sep 2010 $15200
Buy
Report
Report

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

Analysis of the current and future moderate to severe chronic nociceptive pain market with sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key brands, generics, and pipeline products.

Published By Datamonitor
20 Aug 2010 $15200
Buy
Report
Report

Commercial Insight: Inflammatory Bowel Disease - Future market prospects rely on addressing cost and safety

Coverage of the inflammatory bowel disease (IBD) market, including indication-specific 10-year forecasts, detailed brand profiling, opportunities and threats, and a scenario-based case study.

Published By Datamonitor
05 Aug 2010 $15200
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | » »|

No help is available.